Key facts
- This page summarizes Christopher M. Jewell's Form 4 filing for Cartesian Therapeutics, Inc. (RNAC).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Jan 2025, 16:09.
Christopher M. Jewell - 10 Jan 2025 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- RNAC
- Reported as of
- 10 Jan 2025
- Net transaction value
- +$29,070
- SEC form
- 4
- Accepted by SEC
- 13 Jan 2025, 16:09:06 UTC
- Prior SEC filing
- 07 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew Bartholomae, Attorney-in-Fact for Christopher Jewell
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Christopher M. Jewell filed Form 4 for Cartesian Therapeutics, Inc. (RNAC) on 13 Jan 2025.
Change
- Previous filing in this sequence was filed on 07 Jan 2025.
- Current net transaction value: +$29,070.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RNAC
transaction
Common Stock
Options Exercise
- Transaction value
- $29,070
- Shares
- +9,000
- Change %
- +17%
- Price
- $3.23
- Shares after
- 62,490
- Date
- 10 Jan 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RNAC
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -9,000
- Change %
- -12%
- Price
- Shares after
- 67,432
- Date
- 10 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,000
- Exercise price
- $3.23
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option is currently exercisable for an additional 51,089 shares of Common Stock and becomes exercisable for an additional 2,969 shares of Common Stock each month until it is fully exercisable on June 16, 2025.
Footnote F2
On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.